Investigation of Genetic Predictors of the Response to Selective Serotonin Re-Uptake Inhibitors Treatment

Phase 4

Completed

• Conditions: Depression; Antidepressant; Treatment prediction; Mental Health - Depression

• Registration Number: ACTRN12609000295246
• Lead Sponsor: Tartu University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-05-18
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 135

Inclusion Criteria

Both genders
Major Depression diagnosis according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria
At severity of depression of at least moderate as indicated by a Montgomery-Asberg's Depression Rating Scale (MADRS) total score of 22 or higher
Only secondary current comorbid anxiety disorder

Exclusion Criteria

Bipolar disorder
Psychotic disorder or features
Current eating disorders
Mental retardation
Any pervasive developmental disorder or cognitive disorder
Alcohol or drug abuse-related disorders within 12 months prior to baseline
Acute infections, neurological or any other unstable general disorders, serious suicide risk, formal behaviour therapy, or systematic psychotherapy, pregnancy or breastfeeding
A history of hypersensitivity or non-response to escitalopram

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Montgomery-Asberg's Depression Rating Scale (MADRS) (remission score < 12)<br>The genotypic frequencies of serotonin transporter gene were compared between remitters and non-remitters to escitalopram medication. Additionally, the mean change on the MADRS scale was compared between serotonin transporter genotypes at week 12 of escitalopram medication.[The primary outcome was measured at the following time points: week 0, 2, 4, 6, 8, 10 and 12]

Secondary Outcome Measures

Name	Time	Method
Hamilton Rating Scale for Depression (HRSD) (remission score < 8)<br>The genotypic frequencies of serotonin transporter gene were compared between remitters and non-remitters to escitalopram medication. Additionally, the mean change on the HRDS scale was compared between serotonin transporter genotypes at week 12 of escitalopram medication.[The secondary outcome was measured at the following time points: week 0, 2, 4, 6, 8, 10 and 12]